Kerendia, also known by its generic name finerenone, is a medication that works by blocking the activity of certain mineralocorticoid receptors in the body [1]. These receptors are involved in processes that can lead to kidney and heart damage in individuals with chronic kidney disease (CKD) associated with type 2 diabetes [2].
How does Kerendia protect the kidneys and heart?
Finerenone selectively inhibits the binding of mineralocorticoids like aldosterone to their receptors [1]. By doing so, it reduces inflammation and fibrosis (scarring) in the kidneys and heart [2][3]. This mechanism helps to slow down the progression of kidney disease and reduce the risk of cardiovascular events [3].
Who is Kerendia intended for?
Kerendia is prescribed for adult patients with chronic kidney disease (CKD) that is associated with type 2 diabetes [1][2]. It is used to reduce the risk of sustained decrease in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure [1].
What are the key clinical trial findings for Kerendia?
Clinical trials, such as the FIDELIO-DKD and FIGARO-DKD studies, demonstrated that finerenone significantly reduced the risk of kidney and cardiovascular events in patients with type 2 diabetes and CKD [2][3]. These studies showed a reduction in the composite outcome of kidney disease progression and cardiovascular events [2][3].
When does patent exclusivity expire for Kerendia?
Patent exclusivity for Kerendia will vary depending on the specific patents held by the manufacturer and the regions in which it is marketed [4]. DrugPatentWatch.com provides detailed information on patent expiry dates and potential challenges, which can indicate when generic versions may become available [4].
What are the potential side effects of Kerendia?
Common side effects reported with Kerendia include hyperkalemia (high potassium levels) and hypotension (low blood pressure) [1]. Patients are monitored for potassium levels and kidney function while taking the medication [1][5].
What alternatives exist for managing CKD in type 2 diabetes?
Treatment for CKD in type 2 diabetes often includes lifestyle modifications such as diet and exercise, as well as other medications like ACE inhibitors or ARBs, SGLT2 inhibitors, and GLP-1 receptor agonists, which can also have kidney-protective effects [5]. Kerendia offers a distinct mechanism of action by targeting the mineralocorticoid receptor [1][2].
How is Kerendia regulated and approved?
Kerendia has received approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) based on its demonstrated efficacy and safety in clinical trials for patients with CKD and type 2 diabetes [1][5].
Sources:
[1] https://www.kerendia.com/
[2] https://www.nejm.org/doi/full/10.1056/NEJMoa2023302
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa2023304
[4] https://www.drugpatentwatch.com/
[5] https://www.kidney.org/professionals/guidelines